2022
P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer
Lazorwitz A, Teal S, Sheeder J. P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer. Contraception 2022, 116: 92. DOI: 10.1016/j.contraception.2022.09.103.Peer-Reviewed Original ResearchStrong CYP3A inducersBreakthrough ovulationCYP3A inducersE2 concentrationsP4 concentrationsMedian ageOvulation suppressionImplant usersPg/Baseline serum concentrationsContraceptive implant usersEtonogestrel implant usersSerum E2 concentrationsParticipants' median ageSerum P4 concentrationsENG implant usersDrug-drug interactionsRifampin exposureMedian durationENG implantMedian BMIEndogenous estradiolSerum concentrationsSurrogate biomarkerWeeks of exposureEffect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users
Lazorwitz A, Pena M, Sheeder J, Teal S. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2022, 139: 579-587. PMID: 35594123, PMCID: PMC9140306, DOI: 10.1097/aog.0000000000004697.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsBody mass indexPg/Median ageImplant usersEnzyme-inducing antiepileptic drugsMedian body mass indexEffects of topiramateMean percent changeParticipants' median ageOvulatory suppressionTopiramate therapyMedian durationTopiramate useEtonogestrel implantsPharmacokinetic interactionsHealthy womenAntiepileptic drugsMass indexNoninferiority studyImplant useMass spectrometry assayPercent change
2019
Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
Lazorwitz A, Aquilante C, Oreschak K, Sheeder J, Guiahi M, Teal S. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2019, 133: 783-794. PMID: 30870275, PMCID: PMC6448146, DOI: 10.1097/aog.0000000000003189.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsBody mass indexContraceptive implant usersEtonogestrel concentrationsSteroid hormone metabolismImplant useGenetic variantsHepatic enzyme inducersReproductive-age womenImplant usersHormone metabolismPersonalized medicine approachVariant allele frequencyOvulatory suppressionEtonogestrel implantsMass indexHormonal contraceptionConcomitant useWomen's healthPg/Medicine approachParticipant characteristicsSteroid hormonesEnzyme inducersPharmacogenomic investigations
2017
The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. Contraception 2017, 95: 571-577. PMID: 28288788, DOI: 10.1016/j.contraception.2017.03.004.Peer-Reviewed Original ResearchConceptsEtonogestrel concentrationsEtonogestrel contraceptive implantCarbamazepine coadministrationFollicle-like structuresOvulatory suppressionEndometrial thicknessMean ageContraceptive implantsPg/Contraceptive implant usersEtonogestrel implant usersSerum etonogestrel concentrationsReproductive-age womenBody mass indexRisk of pregnancyEffects of carbamazepineImplant usersParticipants' mean ageImpact of carbamazepineEtonogestrel levelsMedian durationPharmacodynamic changesTransvaginal ultrasoundMajority of participantsMass index